Ping-Yang Yeh, Ph.D.
Managing Partner
NovaRadar Bio Venture
Experience
- Dr. Ping-Yang Yeh is a seasoned biopharmaceutical executive with more than 30 years of global experience in biologics research, development, manufacturing, and commercialization. He has held senior leadership positions at Amgen, Biogen, and GSK, and subsequently after returned from USA to Taiwan he served as Chief Technology Officer and Vice President of EirGenix and President of AltruBio Taiwan, leading biologics development, CMC strategy, and CDMO operations.
- Dr. Yeh has extensive expertise in protein therapeutics, monoclonal antibodies, and innovative biologic modalities. He has contributed to the successful commercialization of 18 marketed products, including Repatha®, Blincyto®, Aimovig®, Kyprolis®, Tysabri®, and Plegridy®, and has supported more than 45 IND and related regulatory submissions in the United States and Europe.
- He currently serves as Managing Partner of NovaRadar Bio Venture. The fund focuses on investing next wave of biotech and medtech innovation.
Academic Background
- Dr. Yeh received his Ph.D. in Molecular Pharmaceutics from The University of Utah under the mentorship of Professor Jindřich Kopeček, a pioneer in polymer-based drug delivery systems. He also completed executive education at the MIT Sloan School of Management.